<div id="readability-page-1"><p>Harbor Capital Advisors Inc. boosted its position in  Haemonetics Corporation (NYSE:HAE - Free Report) by 49.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 42,859 shares of the medical instruments supplier's stock after acquiring an additional 14,226 shares during the quarter. Harbor Capital Advisors Inc. owned 0.09% of Haemonetics worth $2,089,000 at the end of the most recent reporting period.</p><p>Several other institutional investors have also added to or reduced their stakes in HAE. Quarry LP boosted its holdings in shares of  Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock valued at $31,000 after purchasing an additional 192 shares in the last quarter.  EverSource Wealth Advisors LLC raised its holdings in shares of  Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 396 shares in the last quarter.  GAMMA Investing LLC lifted its position in shares of  Haemonetics by 59.4% during the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier's stock worth $33,000 after buying an additional 165 shares during the last quarter.  UMB Bank n.a. boosted its stake in  Haemonetics by 91.7% in the second quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier's stock valued at $50,000 after buying an additional 320 shares in the last quarter.  Finally, Elevation Point Wealth Partners LLC acquired a new stake in  Haemonetics in the second quarter valued at about $64,000. 99.67% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several research analysts have commented on the company. Wall Street Zen downgraded Haemonetics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, December 14th. Raymond James Financial  reiterated an &#34;outperform&#34; rating and set a $90.00 price objective on shares of Haemonetics in a research report on Friday, November 14th. JPMorgan Chase &amp; Co. increased their price objective on shares of Haemonetics from $62.00 to $74.00 and gave the company a &#34;neutral&#34; rating in a research note on Friday, December 12th. Robert W. Baird raised their target price on shares of Haemonetics from $87.00 to $99.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, December 15th. Finally, Mizuho upped their price target on shares of Haemonetics from $75.00 to $90.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, seven have issued  a Buy rating, three have assigned  a Hold rating and one  has given a Sell rating to the stock. According to MarketBeat.com, the stock  has an average rating of &#34;Moderate Buy&#34; and an average price target of $84.10.</p><p><b>Get Our Latest Analysis on Haemonetics</b></p><h2>Haemonetics Stock Down 0.4%</h2><p>Shares of NYSE HAE opened at $80.01 on Friday. The company has a 50 day simple moving average of $70.87 and a 200 day simple moving average of $65.16. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32. The firm has a market cap of $3.75 billion, a PE ratio of 23.39, a price-to-earnings-growth ratio of 1.51 and a beta of 0.30. </p><p>Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The firm had revenue of $327.32 million during the quarter, compared to analysts' expectations of $311.61 million. During the same period in the prior year, the company posted $1.12 EPS. The company's revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS.  On average, research analysts forecast that  Haemonetics Corporation will post 4.55 EPS for the current year. </p><h2>Haemonetics Profile</h2> (Free Report)<p>Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.  </p><p>The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Haemonetics</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li><li>Washington prepares for war</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>The McDonald's Secret</li><li>33,000% boom from weird new “AI Fuel?”</li></ul><p><strong>Want to see what other hedge funds are holding HAE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Haemonetics Right Now?</h2><p>Before you consider Haemonetics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.</p><p>While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Harbor Capital Advisors Inc. increased its stake in Haemonetics Corporation by 49.7% in the third quarter, now owning 42,859 shares worth $2,089,000. Other institutional investors also adjusted their holdings. Analysts have mixed ratings on Haemonetics, with an average rating of 'Moderate Buy' and an average price target of $84.10. Haemonetics reported quarterly earnings of $1.27 per share, beating estimates, with revenue of $327.32 million. The company provides blood management solutions globally.</p>

Harbor Capital Advisors Inc. Purchases 14,226 Shares of Haemonetics Corporation $HAE